Myocardial dysfunction caused by abemaciclib: a case report.
A 68-year-old female patient with metastatic breast cancer presented 12 weeks after starting chemotherapy with abemaciclib and fulvestrant with breathlessness, peripheral edema, and weight gain. Brain natriuretic peptide (BNP) and troponin I levels were raised above normal, and chest radiography revealed an increase in the cardiothoracic ratio from 47% before chemotherapy to 55%. The transthoracic echocardiogram showed a reduction in left ventricular ejection fraction from 76% before chemotherapy to 68%. Contrast-enhanced cardiac magnetic resonance imaging (MRI) revealed delayed accumulation in the interventricular septum. Under the diagnosis of abemaciclib-induced myocardial dysfunction and heart failure, abemaciclib was discontinued, and enalapril and furosemide were started. Two months later, imaging revealed a cardiothoracic ratio of 47% with a left ventricular ejection fraction of 73%. A cardiac MRI after three months was normal. This case report demonstrates that cardiac dysfunction caused by abemaciclib is reversible if detected early and treated appropriately.
['Oyakawa|Takuya|T|0000-0001-7637-5501', 'Inagaki|Lina|L|', 'Hua|Zhensheng|Z|', 'Ebihara|Aya|A|', 'Takano|Toshimi|T|', 'Ohno|Shinji|S|', 'Shiga|Taro|T|']
Myocardial dysfunction Abemaciclib Cardiac magnetic resonance imaging Heart failure CDK4/6 inhibitor Cardio-oncology